Intrinsic Therapeutics Secures New CPT Code for Barricaid
Intrinsic Therapeutics, Inc. has recently announced a significant advancement in the field of spinal surgery with the approval of a new Category 1 CPT Code. This code is specifically for bone anchored annular closure, and it includes the Barricaid® Annular Closure Device, which is instrumental for patients undergoing lumbar discectomy aimed at treating herniated discs.
The Importance of CPT Code Approval
The approval of a new Category 1 CPT code is a commendable achievement that underscores the potential of innovative medical technologies. According to reports, the American Medical Association (AMA) CPT Editorial Panel has accepted this code, which is a breakthrough for procedures that utilize the Barricaid device. This device is designed to close large annular defects and is routinely used by orthopaedic spine and neurosurgeons across various healthcare facilities.
Significant Milestone for Barricaid
Dr. Serena Hu, Chief of Orthopaedic Spine Service, emphasized the importance of this new CPT code, stating that it indicates high levels of clinical evidence and efficacy. The categorization not only reflects the rigorous criteria set by the AMA but also signifies the widespread acceptance of Barricaid as a valid therapeutic alternative. Additionally, the accomplishment of securing this code provides a structured pathway for reimbursement, which is vital for healthcare providers.
Key Milestones Achieved
This recent achievement aligns with a series of important milestones for Barricaid over the years. Key achievements include statistical superiority over discectomy alone, FDA Premarket Approval (PMA), and the issuance of a clinical C-Code by the Center for Medicare & Medicaid Services (CMS) for facility payments. Furthermore, ICD-10-CM codes from the Centers for Disease Control and Prevention (CDC) now enable the reporting of large annular defects, which reinforces Barricaid's role in clinical practice.
Collaborative Efforts Behind the Success
Ryan Drant, Chairman of the Board at Intrinsic Therapeutics, expressed gratitude for the collaborative effort of healthcare organizations such as the FDA, CDC, and AMA. These collaborations have been essential in gathering clinical evidence that paves the way for such approvals. The teamwork between surgeons and specialty medical societies has played a significant role in achieving these milestones that ultimately benefit patient care.
About Barricaid Technology
Barricaid is a proprietary technology that has been developed to prevent reherniation and reduce the need for reoperation in patients with large annular defects following lumbar discectomy surgery. It has been successfully implanted in over eleven thousand patients. Barricaid is supported by a wealth of clinical studies spanning eight different patient populations, including two randomized controlled trials and six single-armed trials. A notable multicenter level I randomized controlled trial showcased its superior outcomes in comparison to discectomy alone, further solidifying its place in therapeutic practices.
Frequently Asked Questions
What is the significance of the new CPT code for Barricaid?
The new Category 1 CPT code is essential as it indicates that Barricaid meets stringent clinical evidence requirements and is a reliable option for treating patients with herniated discs.
How does Barricaid work?
Barricaid functions by anchoring the annulus of the disc to prevent reherniation and enhance recovery for patients undergoing lumbar discectomy.
What are the benefits of the CPT code for doctors?
For physicians, the CPT code provides clarity in reimbursement processes and enhances the standard of care for patients, indicating broader acceptance in surgical practices.
How many patients have received the Barricaid implant?
More than eleven thousand patients have been implanted with the Barricaid device, showcasing its extensive usage and clinical validation.
What is the future of Barricaid with the new CPT code?
The new CPT code will play a crucial role in streamlining reimbursement processes, potentially increasing utilization and enhancing patient access to this innovative technology.
